Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $1.33B |
| Gross Profit (TTM) | $792.87M |
| EBITDA | $357.15M |
| Operating Margin | 13.90% |
| Return on Equity | 12.00% |
| Return on Assets | 6.49% |
| Revenue/Share (TTM) | $28.28 |
| Book Value | $17.60 |
| Price-to-Book | 4.28 |
| Price-to-Sales (TTM) | 2.52 |
| EV/Revenue | 3.291 |
| EV/EBITDA | 16.36 |
| Quarterly Earnings Growth (YoY) | 28.40% |
| Quarterly Revenue Growth (YoY) | 4.80% |
| Shares Outstanding | $45.45M |
| Float | $44.86M |
| % Insiders | 1.22% |
| % Institutions | 108.32% |
Volatility is currently contracting
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).
BOSTON, June 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced an update to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Under the new structure, Haemonetics will transition from three reportable segments to two.
BOSTON, June 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Investors need to pay close attention to GBTG stock based on the movements in the options market lately.
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
